Syndax Pharmaceuticals Q2 2024 GAAP EPS $(0.80) Beats $(0.93) Estimate, Sales $3.500M
Portfolio Pulse from Benzinga Newsdesk
Syndax Pharmaceuticals (NASDAQ:SNDX) reported a Q2 2024 GAAP EPS of $(0.80), beating the analyst estimate of $(0.93) by 13.98%. Sales for the quarter were $3.500 million.
August 01, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syndax Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.80), beating the analyst estimate of $(0.93) by 13.98%. Sales for the quarter were $3.500 million.
Syndax Pharmaceuticals' better-than-expected EPS indicates stronger financial performance than anticipated, which is likely to positively impact the stock price in the short term. The sales figure, while modest, supports the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100